Difference between revisions of "Team:Waterloo"
Line 1: | Line 1: | ||
+ | {{Waterloo}} | ||
<html> | <html> | ||
<div class="jumbotron"> | <div class="jumbotron"> | ||
<div class=" header-container container"> | <div class=" header-container container"> | ||
− | <div class=" | + | <div class="text-center"> |
<h2> | <h2> | ||
<font color="#fbb67a">Swappable sgRNA Targets</font> | | <font color="#fbb67a">Swappable sgRNA Targets</font> | | ||
Line 17: | Line 18: | ||
<div id ="contentContainer"> | <div id ="contentContainer"> | ||
</html> | </html> | ||
− | |||
<html> | <html> | ||
<h2>Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems</h2> | <h2>Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems</h2> |
Revision as of 01:42, 15 September 2015
Swappable sgRNA Targets | Engineered PAM Flexibility | Antiviral Protection for Plants
![Waterloo iGEM CRISPieR Logo](/wiki/images/1/1c/Waterloo_crispier_logo.png)
Re-engineering CRISPR-Cas9 with functional applications in eukaryotic systems
CRISPR-Cas9 is an exciting tool for synthetic biologists because it can target and edit genomes with unprecedented specificity. Our team is attempting to re-engineer CRISPR to make it more flexible and easier to use.
We’re making it easy to test different sgRNA designs: restriction sites added to the sgRNA backbone allow 20 nucleotide target sequences to be swapped without excessive cloning.
Additionally, we’re applying recent research on viable mutations within Cas9’s PAM-interacting domain to design (d)Cas9 variants that bind to novel PAM sites, moving towards the goal of a suite of variants that can bind any desired sequence. We believe our re-engineered CRISPR-Cas9 will give biologists increased ability to optimize targeting in many applications.
The application we chose to explore is a proof-of-concept antiviral system defending the model plant Arabidopsis thaliana against Cauliflower Mosaic Virus, which would benefit from testing a large number of possible sgRNAs in the viral genome.